CD138

Creative Biolabs offers a wide range of high-quality CD138 CAR-related products, such as CAR vectors, CAR cells, CAR lentivirus, etc. Please browse the following list to find the appropriate products for you.

Background

The CD138 protein, also known as syndecan-1, is a member of the syndecan family that is expressed in both normal plasma cells and MM tumor cells. CD38 is involved in multiple signaling pathways, such as cell-cell and cell-matrix interactions. Importantly, CD38 plays a crucial role in the carcinogenesis processes, especially in cell proliferation, angiogenesis, tumor invasion, and metastasis, making it a potential therapeutic target for many diseases.

Associated Diseases

• Multiple myeloma
• Breast cancer
• Colorectal cancer
• Hematological malignancies
• Diffuse large B cell lymphoma (DLBCL)

Anti-CD138 CAR-T Services

CD138 CAR Design & Construction

Creative Biolabs has launched a user-friendly online system for customizing CAR, which provides comprehensive options to meet global customers' various needs. Our robust CAR constructions include classical CAR design, as well as various armored CAR constructions, etc.

Fig.1 Schematic diagram of different CD138 CAR construction.¹

Anti-CD138 CAR-T In Vitro Assays

Anti-CD138 CAR-T Expression Test

To directly test CAR expression level, Creative Biolabs provides customers with extensive CAR detection reagents (e.g., special target protein, linker-targeted antibodies), as well as various techniques for CAR expression testing, including but not limited to qPCR, WB, and flow cytometry.

Fig.2 The evaluation of CD138 CAR expression of different CD138 CAR-T cells.¹

Phenotype Analysis of CD138 CAR-T

Phenotypic analysis of CART cells can provide a variety of information, such as the degree of activation, proliferation capacity, depletion, cell population distribution, etc. Creative Biolabs has developed a comprehensive range of test services for CAR-T characterization, such as expansion tests, exhaustion tests, and cell subgroup analysis.

Fig.3 T sell subgroup (effector T and central memory T subsets) analysis of different CD138 CAR-T cells.¹

Anti-CD138 CAR-T Cytokine Release Test

The detection of cytokine production and release illustrate the specificity and effectiveness of CART cells for target cells from the side and provide a reference for further verification. We have developed various appropriate assays for different targets of the CART projects, such as intracellular cytokine tests by flow cytometry, and multiple cytokine arrays.

Fig.4 Cytokine detection of different anti-CD138 CAR-T against CD138⁺ OPM-2 cells (left panel) or CD138^- Raji cells (right panel).¹

Anti-CD138 CAR-T In Vitro Cytotoxicity Assay

To evaluate the tumor killing activity of CAR-T cells in vitro, we offer a range of methods for global customers to choose from, such as ⁵¹Cr release assay, flow cytometry cytotoxicity test, and real-time dynamic cytotoxicity analysis.

Fig.5 The tumor killing activity of different anti-CD138 CAR-T against CD138⁺ OPM-2 cells (left panel) or CD138^- Raji cells (right panel) detected by ⁵¹Cr release assays.¹

Anti-CD138 CAR-T In Vivo Assays

Anti-CD138 CAR-T Cell Therapy Animal Models

Appropriate animal models and in vivo experimental design are critical for CART efficacy validation. Creative Biolabs provides customers with a wide range of animal models to choose from, as well as several customized in vivo experimental designs.

Efficacy Test of Anti-CD138 CAR-T

With our years of experience in the CAR-T fields, we are committed to developing one-stop CAR-T research services for the treatment of various cancers and other diseases. We offer comprehensive in vivo study services, such as CAR-T efficacy and toxicity study services to ensure the safety of CAR-T therapy.

Fig.6 The antitumor activities of the anti-CD138 CAR-T cells in CD138⁺ OPM-2 cell line engrafted NSG mouse model detected by BLI.¹

Reference

1. Sun, Chuang, et al. "Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma." Oncotarget 10.24 (2019): 2369.